SVR (spleen volume reduction) predicts OS (overall survival) in MF (myelofibrosis) patients on PAC (pacritinib) but not BAT (best available therapy): PERSIST-2 landmark OS analysis Meeting Abstract

  

Authors:	Ajufo, H.; Bewersdorf, J. P.; Harrison, C.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; Roman-Torres, K.; Rampal, R.
Abstract Title:	SVR (spleen volume reduction) predicts OS (overall survival) in MF (myelofibrosis) patients on PAC (pacritinib) but not BAT (best available therapy): PERSIST-2 landmark OS analysis
Meeting Title:	11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy
Keywords:	survival; myelofibrosis; jak2; pacritinib; mpn; spleen volume
Journal Title:	Clinical Lymphoma, Myeloma and Leukemia
Volume:	23
Issue:	Suppl. 1
Meeting Dates:	2023 Sep 6-9
Meeting Location:	Houston, TX
ISSN:	2152-2650
Publisher:	Elsevier Inc.
Date Published:	2023-09-01
Start Page:	S382
End Page:	S383
Language:	English
ACCESSION:	WOS:001062479600351
PROVIDER:	wos
DOI:	10.1016/S2152-2650(23)01218-1
Notes:	Meeting Abstract: MPN-111 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/211198